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Inhibitors of plasmin occurring in human blood
Human plasma exerts a very important inhibitory action on plasmin. There are at least five welldefined proteins which inhibit plasmin in a purified system-namely, aX2-macroglobulin, ol-antitrypsin, inter-oz-trypsin inhibitor, antithrombin III-heparin complex, and C,-esterase inhibitor. The physiological inhibitor of plasmin formed in blood, however, is a relatively recently described plasma protein called o02-antiplasmin.2 This inhibitor was independently identified by three groups3-5 and most probably also by a fourth. 6 Upon activation of plasminogen in plasma the formed plasmin is first preferentially bound to Oc2-antiplasmin. Only upon complete activation of plasminogen (concenttation in plasma approximately 1.5 ,umol/l), resulting in saturation of the inhibitor (concentration I ,umol/l), is the excess plasmin neutralised by oX2-macroglobulin. In 9 The reaction between plasmin and aX2-antiplasmin proceeds in at least two steps-a very fast reversible second order reaction followed by a slower irreversible fist order reaction'0 11 and may be represented by
The rate constant ki at pH 7 5 is 3 21 Human plasminogen and plasmin contain structures, known as lysine-binding sites, which are responsible for their interaction not only with amino-acids such as lysine or 6-aminohexanoic acid22-24 but also with fibrin25 and with antiplasmin.4 7 In purified systems native plasminogen (with NH2-terminal glutamic acid) has a weak affinity for fibrin whereas the partially degraded form of plasminogen (with NH2-terminal lysine) has a much stronger affinity.26 When whole plasma is clotted approximately 4% of the plasminogen is specifically bound to fibrin through its lysine-binding sites.27
The rapidity of the plasmin-cx2-antiplasmin reaction is strongly dependent on the availability of free lysine-binding sites and active site in the enzyme. At a concentration of 1 ,umol/l of a2-antiplasmin (the normal plasma concentration) the half life of small amounts of free plasmin can be calculated to be 25 about 100 ms. Plasmin with occupied lysine-binding sites and active site, however, would react at least 100 times slower and have a half life of the order of magnitude of 10 S. 28 Thus fibrinolysis in vivo seems to be regulated at two levels: (1) efficient activation at the fibrin surface of fibrin-bound plasminogen by fibrin-bound plasminogen activator, and (2) degradation of fibrin by fibrin-bound plasmin which is protected from rapid inactivation by x2-antiplasmin since it has both its lysine-binding sites and active site occupied. Since the fibrin-bound plasmin has an estimated half life of about 10 s effective clot dissolution in vivo would also seem to require a continous replacement at the fibrin surface of inactivated plasmin molecules (complexed with 0x2-antiplasmin) by plasminogen molecules. [28] [29] Several lines of evidence indicate that this model for the regulation of fibrinolysis, which was constructed mainly on There are at least three plasma protease inhibitors in addition to oX2-antiplasmin and ao2-macroglobulin that inhibit plasmin in purified systems. These are oxl-antitrypsin, antithrombin III, and Cl-inactivator.34 Inter-oa-trypsin inhibitor is a polyvalent inhibitor and probably also reacts to some extent with plasmin.34 In the presence of normal concentrations of cX2-antiplasmin and oX2-macroglobulin, however, none of these inhibitors play a role in the neutralisation of plasmin formed in the blood.3 35 Purified antithrombin III is a progressive, timedependent inhibitor of purified plasmin. Heparin accelerates the rate of this reaction 50 to 100 fold.36
On the basis of these findings it has been suggested that antithrombin-heparin complex may be a major inhibitor of in-vivo fibrinolysis. The role of antithrombin III-heparin complex as an inhibitor of plasmin formed in plasma has been re-evaluated in vitro and in vivo. 37 38 In the absence of heparin and after complete activation of the plasma plasminogen about 1 % of the formed plasmin binds to antithrombin III. In the presence of therapeutic concentrations of heparin (1-2 IU/ml plasma) this value increased to 2-5% both in vitro and in vivo. These data suggest that the antithrombin IIIheparin complex plays a very limited role in the inactivation of plasmin.
PLASMIN INHIBITORS FROM PLATELETS
Johnson and Schneider39 reported on an antiplasmin activity of bovine platelets which accounted for a major part of the antiplasmin of bovine blood. In human blood, however, the platelets contributed only 1-3 % of the antiplasmin activity. 40 41 The platelet contribution to the total antiplasmin activity of whole human blood is therefore probably small.
Antiplasmin materials in platelets have, however, been characterised to some extent. McDonagh et al. 42 found two antiplasmin activities, one of which was platelet factor XIII and the other one was eluted earlier on Sephadex G-200. Ganguly et al. 43 44 described low molecular weight antiplasmins, which were dialysable in extracts of human platelets. All these plasmin inhibitors are at present poorly characterised.
Inhibitors of plasminogen activation in human blood
The existence in blood of physiological inhibitors to the activation of plasminogen has been much disputed. The demonstration of activation inhibitors in plasma is indeed hampered by two obstacles. Firstly, it is very difficult to measure antiactivator activity in the presence of antiplasmins. Antiactivator activity may, however, be demonstrated in the following ways: complex formation between activator and antiactivator, inhibition of activatorcatalysed hydrolysis of low molecular weight substrates, and inhibition of cleavage of the internal peptide bond in plasminogen.45 Secondly, the various protease inhibitors in plasma may each have some affinity for plasminogen activators and in concert confer some inhibitory activity to the plasma without actually being specific inhibitors. Despite these difficulties it seems, however, that plasma contains components which act or may act as inhibitors of plasminogen activation. But the physiological role of most of these inhibitors is unknown.
Plasminogen activation may occur by three different pathways: an intrinsic or humoral pathway in which all participating components are present in precursor form in the blood, an extrinsic pathway in which the activator originates from tissues or from Collen the vessel wall and is released into the blood by certain stimuli or trauma, and an exogenous pathway in which the activating substances streptokinase or urokinase may be infused for therapeutic purposes. All plasminogen activators studied so far exert their action through hydrolysis of the Arg 560-Val 561 bond in plasminogen.
Intrinsic activation of plasminogen may occur by one or more pathways involving factor XII (Hageman factor), prekallikrein (Fletcher factor), high molecular weight kininogen (Fitzgerald factor), and possibly other components. However, the exact mechanism of this activation as well as its biological role remain unknown.
The plasminogen activator found in blood represents released vascular plasminogen activator, and these activators are similar or identical to the tissue activator but different from urokinase.
The physiological importance of extrinsic plasminogen activators has been inferred from the association between low blood fibrinolytic activity and thrombotic or atherosclerotic disease.
INHIBITORS OF INTRINSIC PLASMINOGEN ACTIVATION
Several inhibitors of intrinsic plasminogen activation occur in human plasma, C1-inactivator,46 an inhibitor of factor XIIa-induced fibrinolysis,47 48 heparin-antithrombin III complex,49 and U2-macroglobulin. 50 Since the physiological role of the intrinsic fibrinolytic pathway is not established the role of these inhibitors in the regulation and control of fibrinolysis thus remains entirely speculative.
INHIBITORS OF EXTRINSIC PLASMINOGEN ACTIVATION
The presence in plasma of inhibitors of extrinsic plasminogen activators forming a complex which dissociates in the presence of fibrin has been postulated already in the 1950s'9 and also in more recent studies. 51 The formation of a reversible activator-activator inhibitor complex which dissociates in the presence of fibrin has been invoked to explain the rapid lysis of fibrin in plasma and the resistance of fibrinogen to degradation by plasmin. 51 The enhancing effect of fibrin on the plasminogen activation may be explained by adsorption of activator and plasminogen to its surface facilitating activation.20 21 28 The evidence for the existence of a specific inhibitor of extrinsic plasminogen activators in plasma, forming a reversible complex, can thus at best be regarded as preliminary. 52 There is good evidence that a significant amount of extrinsic plasminogen activator released in the blood is cleared in vivo by mechanisms other than neutralisation by plasmatic inhibitors. Indeed, whereas 69 This paradox has recently been elucidated.20 70 Native plasminogen (with NH2-terminal glutamic acid) is slowly activated by urokinase, whereas partially degraded plasminogen (with NH2-terminal lysine, valine, or methionine) is rapidly activated.68 69 In the presence of EACA, however, the activation rate of native plasminogen is greatly increased and approaches that of the partially degraded plasminogen. This acceleration has been ascribed to conformational changes in the plasminogen molecule induced by the presence of EACA or removal of the NH2-terminal part of the molecule. The conformational change is probably a result of the dissociation between a site in the NH2-terminal part (residues45-51) and a structure in the plasminogen molecule which binds the antifibrinolytic amino acids ('lysine-binding site').71 72The plasminogen molecule contains at least two such lysine-binding sites.24 73 74 The antifibrinolytic effect of EACA and analogues appears to result from their interference with the binding of plasmin(ogen) to fibrin.25-27 When whole plasma is clotted, approximately 4 % of the plasminogen is specifically bound to fibrin through its lysine-binding sites, and this interaction is abolished by EACA. 27 The specific affinity between plasminogen and fibrin seems to play an important role in the activation of plasminogen with tissue activator which is also specifically adsorbed to fibrin.20 75 Indeed, fibrin markedly potentiates the activation of plasminogen, but this stimulating effect is completely lost in the presence of EACA.20 70 EACA and its more active analogue tranexamic acid have been successfully used to reduce blood loss in essential menorrhagia, prostatectomy, and dental extraction in haemophiliacs.
Physiopathological conditions associated with inhibition of fibrinolysis A number of physiopathological changes in the blood are associated with a delayed lysis of euglobulin clots or dilute blood clots. These include pregnancy, hyperlipidemia, smoking, wine, and beer drinking and possibly atherosclerosis. The molecular mechanisms of inhibition of fibrinolysis by these factors is in most instances unknown.
